Cost-effectiveness of adjunctive eptifibatide in patients undergoing coronary stenting in Germany

European Journal of Health Economics

Volumn 13, Issue 4, 2012, Pages 381-391

  Dewilde, Sarah ^a   Brüggenjürgen, Bernd ^b,c   Nienaber, Christoph ^d   Senges, Jochen ^e   Welte, Robert ^f   Willich, Stefan N ^c  

^a Services in Health Economics   (Belgium)

^b Alpha Care GmbH   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d UNIVERSITY OF ROSTOCK   (Germany)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f GLAXOSMITHKLINE   (Germany)

Author keywords

Cardiovascular; Cost effectiveness; Eptifibatide; Extrapolation; GPIIb IIIa inhibitor; PCI

Indexed keywords

EPTIFIBATIDE;

ADULT; AGED; ARTICLE; CORONARY STENT; COST EFFECTIVENESS ANALYSIS; DEATH; FEMALE; GERMANY; HEART INFARCTION; HIDDEN MARKOV MODEL; HIGH RISK PATIENT; HOSPITAL COST; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; PROBABILITY; QUALITY ADJUSTED LIFE YEAR; REVASCULARIZATION; RISK; SENSITIVITY ANALYSIS; SURVIVAL;

ANGIOPLASTY; COMORBIDITY; COST-BENEFIT ANALYSIS; DOUBLE-BLIND METHOD; FEMALE; GERMANY; HUMANS; LENGTH OF STAY; MALE; MARKOV CHAINS; MIDDLE AGED; MYOCARDIAL INFARCTION; MYOCARDIAL REVASCULARIZATION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; QUALITY-ADJUSTED LIFE YEARS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STENTS;

EID: 84865596054     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-011-0310-6     Document Type: Article

References (40)

1. Statistisches Bundesamt. Krankheitskosten in Mio. € für Deutschland-Gesundheitsberichterstattung des Bundes (2004)
2. Wiesner, G., Grimm, J., Bittner E.: Vorausberechnungen des Herzinfarktgeschehens in Deutschland. Bundesgesundheitsblatt- Gesundheitsforschung-Gesundheitsschutz. 45, 438-445 (2002)
3. Bruckenberger, E.: Herzbericht 2006 mit Transplantationschirurgie. (2007)
4. Brüggenjürgen, B., Lippert, B., Smala, A., et al.: Die stationäre Behandlung der instabilen Angina Pectoris-Abläufe, Ressourcennutzung und Kosten. Gesundheitsökonomie & Qualitätsmanagement. 11, 97-104 (2006)
5. Klever-Deichert, G., Hinzpeter, B., Hunsche, E., et al.: Costs of coronary heart diseases over the remaining life time in coronary heart disease cases-an analysis of the current status of coronary heart disease cases in Germany from the social perspective. ZKardiol. 88, 991-1000 (1999)
6. Hamm, C.W.: Guidelines: Acute coronary syndrome (ACS). II: Acute coronary syndrome with ST-elevation. ZKardiol. 93, 324-341 (2004) (Pubitemid 38568145)
7. Hamm, C.W.: Guidelines: Acute coronary syndrome (ACS). 1: ACS without persistent ST segment elevations. ZKardiol. 93, 72-90 (2004)
8. Kardiologie, D.G.F.: Kardiologische Datenbanken und Register: Klinische Routinedokumentation, Qualitätssicherung und Wissenschaft. (2002)
9. Senges, J., Wienbergen, H., Gitt, A.K.: Die neue Klassifikation der akuten Koronarsyndrome und deren klinische Bedeutung. MedReport. 26(40), 3 (2002)
10. Silber, S., Albertsson, P., Aviles, F.F., et al.: Guidelines for percutaneous coronary interventions. The task force for percutaneous coronary interventions of the European Society of Cardiology. Eur. Heart J. 26, 804-847 (2005)
11. Bertrand, M.E., Simoons, M.L., Fox, K.A., et al.: Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur. Heart J. 23, 1809-1840 (2002)
12. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): A randomised, placebo-controlled trial. Lancet. 356, 2037-2044 (2000)
13. Ohman, E.M., Kleiman, N.S., Gacioch, G., et al.: Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. IMPACT-AMI Investigators. Circulation. 95, 846-854 (1997) (Pubitemid 27091524)
14. O'Shea, J.C., Buller, C.E., Cantor, W.J., et al.: Long-term efficacy of platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention. JAMA. 287, 618-621 (2002) (Pubitemid 34252014)
15. Cohen, D.J., O'Shea, J.C., Pacchiana, C.M., et al.: In-hospital costs of coronary stent implantation with and without eptifibatide (the ESPRIT Trial). Enhanced Suppression of the Platelet IIb/IIIa Receptor with Integrilin. Am. J. Cardiol. 89, 61-64 (2002) (Pubitemid 34066589)
16. Comparative 30-day economic and clinical outcomes of platelet glycoprotein IIb/IIIa inhibitor use during elective percutaneous coronary intervention: Prairie ReoPro versus Integrilin Cost Evaluation (PRICE) Trial. Am. Heart J. 141, 402-409 (2001)
17. Suleiman, M., Gruberg, L., Hammerman, H., et al.: Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: Outcomes, complications and thrombocytopenia during percutaneous coronary intervention. J. Invasive Cardiol. 15, 319-323 (2003) (Pubitemid 36687675)
18. Schweiger, M.J., Changezi, H.U., Naglieri-Prescod, D., et al.: Open-label, sequential comparison of eptifibatide with abciximab for patients undergoing percutaneous coronary intervention. Clin.Ther. 25, 225-234 (2003) (Pubitemid 36206748)
19. Curran, M.P., Keating, G.M.: Eptifibatide: A review of its use in patients with acute coronary syndromes and/or undergoing percutaneous coronary intervention. Drugs. 65, 2009-2035 (2005) (Pubitemid 41327369)
20. Mühlberger, N., Sroczynski, G., Esteban, E., et al.: Cost-effectiveness of primarily human papillomavirus-based cervical cancer screening in settings with currently established Pap screening: A systematic review commissioned by the German Federal Ministry of Health. Int. J. Technol. Assess. Health Care. 24, 184-192 (2008) (Pubitemid 351519518)
21. Kobelt, G., Lindgren, P., Singh, A., et al.: Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. Ann. Rheum. Dis. 64, 1174-1179 (2005) (Pubitemid 41113352)
22. Puma, J.A., Banko, L.T., Pieper, K.S., et al.: Clinical characteristics predict benefits from eptifibatide therapy during coronary stenting: Insights from the Enhanced Suppression of the Platelet IIb/IIIa Receptor With Integrilin Therapy (ESPRIT) trial. J. Am. Coll. Cardiol. 47, 715-718 (2006) (Pubitemid 43243090)
23. InEK-Institut für das Entgeltsystem im Krankenhaus. G-DRG 2006. (2006)
24. AOK-Bundesverband. Ü bersicht über die für 2006 gültigen Landesbasisfallwerte in den einzelnen Bundesländern. (2006)
25. Willich, S., Brüggenjürgen, B.: Sirolimus-eluting vs bare metal stents for the reduction of coronary restenosis: Outcome and economic analysis of the GERSHWIN study. (2007)
26. InEK-Institut für das Entgeltsystem im Krankenhaus. G-DRG Browser Version 2005-2007. (2007).
27. Brüggenjürgen, B., Rupprecht, H.-J., Willich, S.N., et al.: Cost of artherothrombotic diseases-myocardial infarction, ischaemic stroke and peripheral arterial occlusive disease-in Germany. J. Public Health. 13, 216-224 (2005) (Pubitemid 41040220)
28. Kassenärztliche Bundesvereinigung. EMB 2000 plus. (2007)
29. Augsburg, Berlin, Hamburg, Ludwigshafen, Rostock and Rüsselsheim. Experten Board. (2006)
30. Sonntag, F., Schö ffski, O., Haß, B.: Metoprololsuccinat zur Behandlung der chronischen Herzinsuffizienz. MMW Fortschritte in der Medizin 147(24), 39 (2005)
31. van Stel, H.F., Buskens, E.: Comparison of the SF-6D and the EQ-5D in patients with coronary heart disease. Health Qual. Life Outcomes. 4, 20 (2006)
32. Kuntz, K.M., Tsevat, J., Goldman, L., et al.: Cost-effectiveness of routine coronary angiography after acute myocardial infarction. Circulation. 94, 957-965 (1996) (Pubitemid 26292847)
33. Plosker, G.L., Ibbotson, T.: Eptifibatide: A pharmacoeconomic review of its use in percutaneous coronary intervention and acute coronary syndromes. Pharmacoeconomics. 21, 885-912 (2003) (Pubitemid 37056056)
34. Salame, M.Y., More, R.S., Verheye, S., et al.: The use of adjunctive GPIIb/IIIa inhibitors in patients with unstable angina/non-Q-wave MI undergoing percutaneous coronary intervention. Int. J. Cardiovasc Intervent. 2, 207-215 (1999) (Pubitemid 30090227)
35. Hillegass, W.B., Newman, A.R., Raco, D.L.: Economic issues in glycoprotein IIb/IIIa receptor therapy. Am. Heart J. 138, S24-S32 (1999) (Pubitemid 29334770)
36. McCollam, P.L., Foster, D.A., Riesmeyer, J.S.: Cost and effectiveness of glycoprotein IIb/IIIa-receptor inhibitors in patients with acute myocardial infarction undergoing percutaneous coronary intervention. Am. J. Health Syst. Pharm. 60, 1251-1256 (2003) (Pubitemid 38500290)
37. Coons, J.C., Seybert, A.L., Saul, M.I., et al.: Outcomes and costs of abciximab versus eptifibatide for percutaneous coronary intervention. Ann. Pharmacother. 39, 1621-1626 (2005) (Pubitemid 41393119)
38. Le Pen, C., Lilliu, H.: Choice of GPIIb/IIIa antagonist in percutaneous coronary intervention: How should economic criteria be factored in? Pharm. World Sci. 27, 83-91 (2005) (Pubitemid 40755033)
39. Hillegass, W.B., Newman, A.R., Raco, D.L.: Glycoprotein IIb/IIIa receptor therapy in percutaneous coronary intervention and non-ST-segment elevation acute coronary syndromes. Estimating the economic implications. Pharmacoeconomics. 19, 41-55 (2001) (Pubitemid 32113371)
40. Glaser, R., Glick, H.A., Herrmann, H.C., et al.: The role of risk stratification in the decision to provide upstream versus selective glycoprotein IIb/IIIa inhibitors for acute coronary syndromes: A cost-effectiveness analysis. J. Am. Coll. Cardiol. 47, 529-537 (2006) (Pubitemid 43173442)